<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901328</url>
  </required_header>
  <id_info>
    <org_study_id>2402-004</org_study_id>
    <secondary_id>5945-OIC-12-03</secondary_id>
    <nct_id>NCT01901328</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment
      of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer
      pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled, parallel-group study in participants
      with OIC taking opioid therapy for chronic non-cancer pain. Approximately 600 participants
      (300 participants per treatment group) with OIC will be randomized at approximately 75 study
      centers to receive either oral 0.25 mg CB-5945 BID or oral matching placebo BID for the
      12-week double-blind treatment period, followed by a 4-week follow-up period. All randomized
      participants will be evaluated for clinical response for duration of their study
      participation. All participants will be followed for safety for 4 weeks after last dose of
      the study medication, regardless of when they discontinue study medication. The clinical
      study report for this study includes pooled results for studies 5945-OIC-12-02 (NCT01901302)
      5945-OIC-12-03 (NCT01901328), and 5945-OIC-12-04 (NCT01901341).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision due to lack of enrollment.
  </why_stopped>
  <start_date type="Actual">April 7, 2013</start_date>
  <completion_date type="Actual">February 13, 2014</completion_date>
  <primary_completion_date type="Actual">February 13, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Spontaneous Bowel Movement (SBM) Responder Rates at 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>A Spontaneous Bowel Movement (SBM) Weekly Responder (calculated for each week of the 12-week double-blind treatment period) is a participant who has ≥ 3 SBMs for the week and an increase from baseline of ≥1 SBM for the specified week, based on at least 4 Available Data Days (ADDs) during the week. For the definition of the primary efficacy endpoint, Overall SBM Responder is a participant who is a Weekly SBM Responder for 9 of the 12 weeks of the double-blind treatment period, including 3 of the last 4 weeks (Weeks 9, 10, 11 and 12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Chronic Opioid-Related Gastrointestinal Symptom Scale (CORGISS) Scores at 12 Weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The CORGISS is designed to assess GI symptoms related to opioid use in patients with chronic non-cancer pain. The CORGISS asks participants to rate the severity of GI symptoms over the previous 24 hours, with answers ranging from 0 (&quot;did not experience&quot;) to 4 (&quot;very severe&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Complete Spontaneous Bowel Movement (CSBM) Responder Rates at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>A CSBM Weekly Responder is a subject who has ≥ 3 CSBMs for the specified week and an increase from baseline of ≥1 CSBM for the week. An Overall CSBM Responder is a subject who is a Weekly CSBM Responder for 9 of the 12 weeks of the double-blind treatment period, including 3 of the last 4 weeks (Weeks 9, 10, 11 and 12).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adjudicated Cardiovascular, Gastrointestinal and Central Opioid Withdrawal Events</measure>
    <time_frame>Baseline through 16 weeks</time_frame>
    <description>Cardiovascular (CV) events of interested included myocardial infarction, unstable angina, cardiovascular accident, congestive heart failure, serious arrhythmia, resuscitated cardiac arrest, and death.
Gastrointestinal (GI) events of interest included emergency department visits for SAEs of gastroenteritis, hepatitis, pancreatitis, nausea, vomiting, diarrhea, and abdominal pain or cramping.
Central opioid withdrawal events of interest included opioid withdrawal syndrome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Opioid-Induced Constipation</condition>
  <arm_group>
    <arm_group_label>CB-5945</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally BID for a 12-week treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-5945</intervention_name>
    <arm_group_label>CB-5945</arm_group_label>
    <other_name>Bevenopran</other_name>
    <other_name>ADL5945</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Is taking a stable daily dose of opioids of ≥30 mg morphine equivalent total daily
             dose (METDD) for chronic non-cancer pain

          -  Has constipation that is caused by the chronic use of opioids

          -  Is willing to use only the study provided laxative(s) and to discontinue use of all
             other laxatives, enemas, stool softeners, and other medications to treat constipation
             (e.g., lubiprostone) from Screening until the last study assessment

        Key Exclusion Criteria:

          -  Has gastrointestinal (GI) or pelvic disorders known to affect bowel transit (for
             example [e.g.], obstruction) or contribute to bowel dysfunction

          -  Has evidence of intestinal obstruction

          -  Has a history of rectal bleeding not due to hemorrhoids or fissures within 6 months of
             screening

          -  Has an active malignancy of any type (participants with a history of successfully
             treated malignancy &gt;5 years before the scheduled administration of study medication
             and participants with treated basal or squamous cell cancer may be enrolled)

          -  Is taking antispasmodics (e.g., dicyclomine), antidiarrheals (e.g., loperamide),
             prokinetics (e.g., metoclopramide), or locally acting chloride channel activators
             (e.g., lubiprostone)

          -  Is taking non-opioid medications known to cause constipation (e.g., iron sulfate
             therapy, tricyclic antidepressants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <results_first_submitted>April 19, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2015</results_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Constipation</keyword>
  <keyword>Chronic</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Due to difficulties with enrollment, this study was terminated early.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CB-5945</title>
          <description>0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered orally BID for a 12-week treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>CB-5945</title>
          <description>0.25 mg CB-5945 administered orally BID for a 12-week treatment period</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered orally BID for a 12-week treatment period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>LTE18</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BTWN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GTE65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Spontaneous Bowel Movement (SBM) Responder Rates at 12-weeks</title>
        <description>A Spontaneous Bowel Movement (SBM) Weekly Responder (calculated for each week of the 12-week double-blind treatment period) is a participant who has ≥ 3 SBMs for the week and an increase from baseline of ≥1 SBM for the specified week, based on at least 4 Available Data Days (ADDs) during the week. For the definition of the primary efficacy endpoint, Overall SBM Responder is a participant who is a Weekly SBM Responder for 9 of the 12 weeks of the double-blind treatment period, including 3 of the last 4 weeks (Weeks 9, 10, 11 and 12).</description>
        <time_frame>12 weeks</time_frame>
        <population>Zero participants were analyzed, and no data was collected for this measure. Due to lack of enrollment, the study was terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-5945</title>
            <description>0.25 mg CB-5945 administered orally BID for a 12-week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally BID for a 12-week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Spontaneous Bowel Movement (SBM) Responder Rates at 12-weeks</title>
          <description>A Spontaneous Bowel Movement (SBM) Weekly Responder (calculated for each week of the 12-week double-blind treatment period) is a participant who has ≥ 3 SBMs for the week and an increase from baseline of ≥1 SBM for the specified week, based on at least 4 Available Data Days (ADDs) during the week. For the definition of the primary efficacy endpoint, Overall SBM Responder is a participant who is a Weekly SBM Responder for 9 of the 12 weeks of the double-blind treatment period, including 3 of the last 4 weeks (Weeks 9, 10, 11 and 12).</description>
          <population>Zero participants were analyzed, and no data was collected for this measure. Due to lack of enrollment, the study was terminated early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Chronic Opioid-Related Gastrointestinal Symptom Scale (CORGISS) Scores at 12 Weeks</title>
        <description>The CORGISS is designed to assess GI symptoms related to opioid use in patients with chronic non-cancer pain. The CORGISS asks participants to rate the severity of GI symptoms over the previous 24 hours, with answers ranging from 0 (&quot;did not experience&quot;) to 4 (&quot;very severe&quot;).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Zero participants were analyzed, and no data was collected for this measure. Due to lack of enrollment, the study was terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-5945</title>
            <description>0.25 mg CB-5945 administered orally BID for a 12-week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally BID for a 12-week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Chronic Opioid-Related Gastrointestinal Symptom Scale (CORGISS) Scores at 12 Weeks</title>
          <description>The CORGISS is designed to assess GI symptoms related to opioid use in patients with chronic non-cancer pain. The CORGISS asks participants to rate the severity of GI symptoms over the previous 24 hours, with answers ranging from 0 (&quot;did not experience&quot;) to 4 (&quot;very severe&quot;).</description>
          <population>Zero participants were analyzed, and no data was collected for this measure. Due to lack of enrollment, the study was terminated early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Complete Spontaneous Bowel Movement (CSBM) Responder Rates at 12 Weeks</title>
        <description>A CSBM Weekly Responder is a subject who has ≥ 3 CSBMs for the specified week and an increase from baseline of ≥1 CSBM for the week. An Overall CSBM Responder is a subject who is a Weekly CSBM Responder for 9 of the 12 weeks of the double-blind treatment period, including 3 of the last 4 weeks (Weeks 9, 10, 11 and 12).</description>
        <time_frame>12 weeks</time_frame>
        <population>Zero participants were analyzed, and no data was collected for this measure. Due to lack of enrollment, the study was terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>CB-5945</title>
            <description>0.25 mg CB-5945 administered orally BID for a 12-week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally BID for a 12-week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Complete Spontaneous Bowel Movement (CSBM) Responder Rates at 12 Weeks</title>
          <description>A CSBM Weekly Responder is a subject who has ≥ 3 CSBMs for the specified week and an increase from baseline of ≥1 CSBM for the week. An Overall CSBM Responder is a subject who is a Weekly CSBM Responder for 9 of the 12 weeks of the double-blind treatment period, including 3 of the last 4 weeks (Weeks 9, 10, 11 and 12).</description>
          <population>Zero participants were analyzed, and no data was collected for this measure. Due to lack of enrollment, the study was terminated early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjudicated Cardiovascular, Gastrointestinal and Central Opioid Withdrawal Events</title>
        <description>Cardiovascular (CV) events of interested included myocardial infarction, unstable angina, cardiovascular accident, congestive heart failure, serious arrhythmia, resuscitated cardiac arrest, and death.
Gastrointestinal (GI) events of interest included emergency department visits for SAEs of gastroenteritis, hepatitis, pancreatitis, nausea, vomiting, diarrhea, and abdominal pain or cramping.
Central opioid withdrawal events of interest included opioid withdrawal syndrome.</description>
        <time_frame>Baseline through 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CB-5945</title>
            <description>0.25 milligrams CB-5945 administered orally BID for a 12-week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally BID for a 12-week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Cardiovascular, Gastrointestinal and Central Opioid Withdrawal Events</title>
          <description>Cardiovascular (CV) events of interested included myocardial infarction, unstable angina, cardiovascular accident, congestive heart failure, serious arrhythmia, resuscitated cardiac arrest, and death.
Gastrointestinal (GI) events of interest included emergency department visits for SAEs of gastroenteritis, hepatitis, pancreatitis, nausea, vomiting, diarrhea, and abdominal pain or cramping.
Central opioid withdrawal events of interest included opioid withdrawal syndrome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at Least One Confirmed CV Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at Least One Confirmed GI Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at Least One Confirmed OW Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 16 weeks</time_frame>
      <desc>SAEs that occurred before the first dose of double-blind study medication were only included in the safety database.</desc>
      <group_list>
        <group group_id="E1">
          <title>CB-5945</title>
          <description>0.25 mg CB-5945 administered orally BID for a 12-week treatment period</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered orally BID for a 12-week treatment period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Due to difficulties with enrollment, this study was terminated early.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President, Clinical Research</name_or_title>
      <organization>Cubist Pharmaceuticals</organization>
      <phone>(781) 860-8660</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

